Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization

作者：Gils Ann^*; Vande Casteele Niels; Poppe Raf; Van de Wouwer Marlies; Compernolle Griet; Peeters Miet; Brouwers Els; Vermeire Severine; Geukens Nick; Declerck Paul J

来源：Therapeutic Drug Monitoring, 2014, 36(5): 669-673.

DOI：10.1097/ftd.0000000000000074

• adalimumab
• inflammatory bowel disease
• antibody standard
• ELISA
• immunogenicity
• therapeutic drug monitoring

Background: Therapeutic drug monitoring of adalimumab (ADM) has been introduced recently. When no detectable ADM serum concentrations can be found, the formation of antidrug antibodies (ADA) should be investigated. A variety of assays to measure the occurrence of ADA have been developed. Results are expressed as arbitrary units or as a titration value. The aim was to develop a monoclonal antibody (MA) that could serve as a universal calibrator to quantify the amount of ADA in ADM-treated patients.
Methods: Hybridoma technology was used to generate a MA toward ADM. The functionality of the MA was tested in a bridging enzyme linked immunosorbent assay (ELISA) setup and in a cell-based assay. Sera from 25 anti-tumor necrosis factor naive patients with inflammatory bowel disease were used to determine the cutoff values. Sera from 9 ADM-treated patients with inflammatory bowel disease, with undetectable serum concentrations of ADM were used to quantify the ADA response.
Results: In this study, MA-ADM6A10, an IgG1 that can be used as a calibrator in both an ELISA to quantify the amount of binding antibodies and in a cell-based assay to quantify the amount of neutralizing antibodies, was generated. Combining the results of both assays showed that the sera with high concentrations of anti-ADM binding antibodies also had the highest neutralizing capacity.
Conclusions: The availability of a universal calibrator could facilitate the interlaboratory harmonization of antibody titers in patients who develop anti-adalimumab antibodies.

• 出版日期2014-10